# Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients

> **NCT02011841** · PHASE3 · WITHDRAWN · sponsor: **Seoul National University Hospital**

## Conditions studied

- Spontaneous Bacterial Peritonitis

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Ciprofloxacin

## Key facts

- **NCT ID:** NCT02011841
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-01
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** We failed to recruit patients
- **Last updated:** 2017-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02011841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02011841, "Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02011841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*